Unlocking a $750 Million Opportunity: Krystal Biotech's Vyjuvek and its Potent Impact on Dystrophic Epidermolysis Bullosa Treatment
Portfolio Pulse from Vandana Singh
The FDA has approved Krystal Biotech's Vyjuvek for treating patients with dystrophic epidermolysis bullosa (DEB). The annual pricing per patient is estimated at $485,000 after government discounts. Krystal estimates 3,000 total DEB patients in the US, with a $750 million market opportunity. Analysts project $900 million in US peak sales.
May 22, 2023 | 9:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech's FDA-approved Vyjuvek for DEB treatment unlocks a $750 million market opportunity, with analysts projecting $900 million in US peak sales.
The FDA approval of Vyjuvek for DEB treatment is a significant milestone for Krystal Biotech, as it is the first and only approved medicine for this condition. The estimated market opportunity of $750 million and analysts' projection of $900 million in US peak sales indicate a strong potential for revenue growth. This positive news has already impacted the stock price, with KRYS shares up 22.40% at $117.53.
CONFIDENCE 90
IMPORTANCE 100
RELEVANCE 100